PPD
Executive Summary
Genupro subsidiary has dapoxetine in Phase II trials for premature ejaculation, CEO Fred Eshelman reported during an April 21 conference call. The company has enrolled 138 of a planned 150 patients in the study. Proof of concept may be established in the third quarter, at which time Lilly has the option to re-license the drug in exchange for a milestone payment. Genupro was established last year to develop genitourinary compounds licensed from Lilly